1. Home
  2. TBPH vs PSNYW Comparison

TBPH vs PSNYW Comparison

Compare TBPH & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • PSNYW
  • Stock Information
  • Founded
  • TBPH 2013
  • PSNYW 2017
  • Country
  • TBPH United States
  • PSNYW Sweden
  • Employees
  • TBPH N/A
  • PSNYW N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • PSNYW Auto Manufacturing
  • Sector
  • TBPH Health Care
  • PSNYW Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • PSNYW Nasdaq
  • Market Cap
  • TBPH 452.3M
  • PSNYW 442.3M
  • IPO Year
  • TBPH N/A
  • PSNYW N/A
  • Fundamental
  • Price
  • TBPH $9.32
  • PSNYW $0.19
  • Analyst Decision
  • TBPH Buy
  • PSNYW
  • Analyst Count
  • TBPH 4
  • PSNYW 0
  • Target Price
  • TBPH $13.75
  • PSNYW N/A
  • AVG Volume (30 Days)
  • TBPH 202.5K
  • PSNYW 82.8K
  • Earning Date
  • TBPH 02-26-2025
  • PSNYW 03-06-2025
  • Dividend Yield
  • TBPH N/A
  • PSNYW N/A
  • EPS Growth
  • TBPH N/A
  • PSNYW N/A
  • EPS
  • TBPH N/A
  • PSNYW N/A
  • Revenue
  • TBPH $63,192,000.00
  • PSNYW $2,046,740,000.00
  • Revenue This Year
  • TBPH $11.41
  • PSNYW N/A
  • Revenue Next Year
  • TBPH $37.36
  • PSNYW $69.12
  • P/E Ratio
  • TBPH N/A
  • PSNYW N/A
  • Revenue Growth
  • TBPH 15.93
  • PSNYW N/A
  • 52 Week Low
  • TBPH $7.44
  • PSNYW $0.09
  • 52 Week High
  • TBPH $10.90
  • PSNYW $0.61
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 47.75
  • PSNYW 45.84
  • Support Level
  • TBPH $8.85
  • PSNYW $0.20
  • Resistance Level
  • TBPH $10.05
  • PSNYW $0.25
  • Average True Range (ATR)
  • TBPH 0.38
  • PSNYW 0.02
  • MACD
  • TBPH 0.01
  • PSNYW -0.00
  • Stochastic Oscillator
  • TBPH 38.75
  • PSNYW 20.00

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.

Share on Social Networks: